ANI Pharmaceuticals Beats On Diversified Strength, But A Second Cortrophin Guidance Cut Overshadows The Egetis Deal

ANI Pharmaceuticals delivered a clear beat in the third quarter. Earnings were $2.28 per share against a $1.80 consensus, a 26.7% surprise, on revenue of $290.78 million versus the $280.17 million expected. Earnings grew 39.0% year over year and revenue rose 27.6%. Top-line growth has now accelerated for three straight quarters, from roughly 20% in Q1 to 26% in Q2 to 28% in Q3. Under its own definitions, the company reported adjusted non-GAAP EPS of $2.70 and GAAP diluted EPS of $1.51. The gap reflects add-backs for amortization, stock compensation and other items. The headline is strong, but the most important number in the release was not a beat. It was a cut. Cortrophin Gel, the franchise the investment case is built around, missed management's own target again, and full-year guidance for the product was lowered for the second consecutive quarter. That is the central tension.

The quality of the beat deserves scrutiny because much of the upside came from outside Cortrophin:

• **Generics** rose 10.7% to $104.5 million, with 16 launches year to date.
• **ILUVIEN** jumped 34.1% to $22.3 million, helped partly by the phasing of international shipments, after declining in Q2.
• **Harmony Agreement revenue** contributed $11.5 million, including a $2.0 million milestone, and boosted mix. Non-GAAP gross margin expanded 260 basis points year over year to 61.8%, although that was below Q2's 62.6%.

Adjusted EBITDA climbed 39.8% to $83.3 million. Operating leverage was not the driver, however: non-GAAP SG&A rose 32.4%, faster than revenue, as ANI built out its gout sales effort.

Cortrophin revenue of $138.7 million was up 36.1% year over year, but it fell short of the $143-153 million range management guided on the Q2 call. Full-year Cortrophin guidance is now $480-500 million, down from $520-540 million in August and $540-575 million originally. Implied growth has stepped down from 55-65% to roughly 40%.

Management blamed capacity constraints in its specialty pharmacy network and slow enrollment-to-fulfillment conversion at prescriber offices new to ACTH therapy, such as primary care and podiatry. It pointed to strong leading indicators:

• new gout patient cases doubled quarter over quarter;
• gout prescribers rose about 67%;
• October set a record for new cases in existing specialties;
• time-to-first-fill showed early improvement after the pharmacy network expansion.

The call preserved a credible demand story. Bears still have legitimate ammunition. This follows Q1 insurance re-verification problems, making conversion shortfalls a recurring pattern rather than a one-off. Analysts also flagged softer IQVIA prescription data, which raises the question of whether volume, not just fulfillment, is slowing.

The rest of the guidance tells a different story:

• total revenue was narrowed to $1.085-1.125 billion, leaving the midpoint unchanged;
• adjusted EBITDA guidance was lifted to $290-300 million;
• adjusted EPS guidance rose to $9.37-9.71;
• ILUVIEN and gross margin targets moved higher.

In effect, the diversified portfolio is absorbing a roughly $40 million Cortrophin shortfall. That is a real strength, but it is not the growth engine investors are paying for.

The Egetis offer changes the setup. The roughly $560 million all-cash deal, about $434 million in enterprise value after adjusting for Egetis' priority review voucher sale, would add EMCITATE. It is the first approved treatment for MCT8 deficiency in the U.S. and Europe, with orphan exclusivity and patent protection into 2045. Management cited peak sales potential above $300 million. The costs are tangible:

• the deal is expected to dilute adjusted EBITDA and EPS in year one;
• pro forma net leverage rises to about 2.7x from 1.0x at Q2;
• no MCT8 revenue guidance was given;
• the roughly $950,000 U.S. price versus about $200,000 in Europe invites most-favored-nation pricing scrutiny.

Closing also requires 90% acceptance, with roughly 42% already committed.

Investors came in braced for trouble. Earnings Whispers sentiment improved sharply, from -0.35 at the prior report to -0.02, moving from clearly negative to roughly neutral. Price action stayed weak. As of the pre-report snapshot, shares were at $71.65:

• down 7.1% since the open after the August report;
• 7.5% below the 200-day moving average;
• just 3% above the $69.58 52-week low set on September 11 during this inter-earnings period.

Price and AVWAP trend readings remain negative, even as sequential growth reads positive. That captures the split between solid consolidated results and a stock that has not been rewarded for them.

The bottom line is that ANI posted an accelerating, high-quality consolidated quarter and raised profit guidance, but the core Cortrophin thesis took another credibility hit. The Egetis deal adds a promising long-dated rare-disease asset at the cost of near-term dilution and higher leverage. Until specialty pharmacy fixes show up in Cortrophin revenue rather than leading indicators, the stock's discount to its 200-day average reflects a credibility gap that one beat does not close.

Read our earnings preview for ANI Pharmaceuticals Inc: https://www.earningswhispers.com/article/ANIP/22040

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.